For research use only. Not for therapeutic Use.
Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).
Harpagoside (200 μM; 2 h+1 h, 6 h) inhibits lipopolysaccharide (100 ng/mL LPS)-induced mRNA levels and protein expression of cyclooxygenase 2 and inducible nitric oxide in HepG2 cells[2].
Harpagoside (0.1-200 μM; 4 h+1 h, 6 h) dose-dependently inhibits LPS-stimulated NF-κB promoter activity and interferes with the activation of gene transcription[2].
Harpagoside (5 mg/kg; 15 mg/kg; po; once daily for 60 days) has potential neuroprotective effects against Aβ intoxication in an Aβ1-40-induced rat Alzheimer’s disease (AD) model[3].
| Catalog Number | R015015 |
| CAS Number | 19210-12-9 |
| Synonyms | [(1S,4aS,5R,7S,7aS)-4a,5-dihydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,5,6,7a-tetrahydrocyclopenta[c]pyran-7-yl] (E)-3-phenylprop-2-enoate |
| Molecular Formula | C24H30O11 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H30O11/c1-23(35-16(27)8-7-13-5-3-2-4-6-13)11-15(26)24(31)9-10-32-22(20(23)24)34-21-19(30)18(29)17(28)14(12-25)33-21/h2-10,14-15,17-22,25-26,28-31H,11-12H2,1H3/b8-7+/t14-,15-,17-,18+,19-,20-,21+,22+,23+,24-/m1/s1 |
| InChIKey | KVRQGMOSZKPBNS-FMHLWDFHSA-N |
| SMILES | CC1(CC(C2(C1C(OC=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O)OC(=O)C=CC4=CC=CC=C4 |
| Reference | [1]. Anauate MC, et al. Effect of isolated fractions of Harpagophytum procumbens D.C. (devil’s claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay. Phytother Res. 2010 Sep;24(9):1365-9. |
